Going Concern (worsened) — Substantial doubt persists with auditor qualification; current filing specifies July 2026 cash depletion vs generic 12-month language in baseline.
Material Weakness (removed) — Material weakness in clinical trial expense accruals was remediated as of December 31, 2024 and is no longer disclosed.

NASDAQ: ACTU ACTUATE THERAPEUTICS, INC. 10-K

Actuate reports positive Phase 2 pancreatic cancer data but flags cash depletion by July 2026

Filed March 26, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 13, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade ACTU commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 4, 2026 3:32 AM